Incidence of intermediate syndrome in organophosphorous poisoning

J Assoc Physicians India. 1995 May;43(5):321-3.

Abstract

Seventy two patients admitted to the Intensive Care Unit following ingestion of organophosphorus compounds were studied prospectively with two different doses of pralidoxime (PAM). One group received 1 gm immediately after admission and no further PAM and the other group received infusion of PAM, 1 gm 8 hourly for four days (total 12 gms). The incidence of type II paralysis or intermediate syndrome was 47%. We observed a higher incidence in the 4 days of infusion of PAM group (61%) (20 patients) as compared to the single Bolus dose group (39%) (13 patients). Relative risk 1.48 (confidence interval = 0.9-2.4).

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Cholinesterase Reactivators / administration & dosage*
  • Cholinesterase Reactivators / adverse effects
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Drug Administration Schedule
  • Drug Overdose / drug therapy*
  • Female
  • Humans
  • Infusions, Intravenous
  • Male
  • Organophosphate Poisoning*
  • Paralysis / chemically induced*
  • Paralysis / drug therapy
  • Pralidoxime Compounds / administration & dosage*
  • Pralidoxime Compounds / adverse effects
  • Prospective Studies
  • Respiratory Paralysis / chemically induced*
  • Respiratory Paralysis / drug therapy
  • Syndrome

Substances

  • Cholinesterase Reactivators
  • Pralidoxime Compounds
  • pralidoxime